Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model

The correspondence by S. Ozsu concerns several issues. The first issue is the identification of low-risk patients with acute pulmonary embolism. According to the 2014 European Society of Cardiology (ESC) guidelines, a Simplified Pulmonary Embolism Severity Index (sPESI) score of zero efficiently identifies patients at low risk for death; assessment of right ventricle dysfunction by imaging or biomarkers is optional in patients with sPESI 0 [1]. Our study reports a simulation of what would happen in clinical practice by adopting the risk stratification model proposed by the 2014 ESC guidelines (see table 2 of our article) [2]. Patients at low risk (sPESI 0) would not undergo assessment of right ventricle dysfunction by imaging or biomarkers. The warning here is that ∼40% of these patients have right ventricle dysfunction at imaging and ∼30% of them have increased troponin levels [2]. Are these abnormalities of clinical value? It depends on the clinical relevance of the 0.5% observed 30-day mortality. In our opinion, 0.5% mortality at 30 days does not justify the mandatory assessment of right ventricle dysfunction and biomarkers in all patients with sPESI 0. However, we believe that right to left ventricle dimension ratio should be evaluated and reported for all patients who have computed tomography angiography for the diagnosis of pulmonary embolism [3]. This assessment will help clinicians to properly select low-risk patients (sPESI 0 and no right ventricle dilation) without performing any additional test. Further studies are needed to improve risk stratification in acute pulmonary embolism at intermediate risk for death